New funding to support building image-guided surgical navigation platformBOSTON--(BUSINESS WIRE)--Method AI, a medical technology company focused on improving oncology outcomes...
New funding to support building image-guided surgical navigation platformBOSTON--(BUSINESS WIRE)--Method AI, a medical technology company focused on improving oncology outcomes...
Alnylam Pharmaceuticals, BeOne Medicines, Intercept Pharmaceuticals, Merck, Pfizer, and Sanofi among biopharmas sharing strategies that set future direction Veeva to...
NEW CASTLE, Del., Aug. 21, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, is proud to announce...
Leading Pharmaceutical Manufacturers, Contract Research Organizations, and Academic Medical Centers Collaborate on Global Research Project Using DistillerSR. OTTAWA, ONTARIO /...
Esteemed expert in the regulation and development of biopharmaceuticals, with more than three decades of experience spanning government, industry, and...
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogsCompany...
US Food and Drug Administration (FDA) has accepted the company's Type C meeting request and SKNJCT-003 Phase 2 study has...
Dr. Javier J. Zulueta enters boardroom as Chief Medical Officer, Pulmonology, with potential of changing the lung cancer survival curve...
With one easy blood test, Molecular You measures over 250 biomarkers, enabling more powerful and comprehensive insights for preventive and...
A New Era of Human-Centered AI for Hospitals, Designed to Work Seamlessly with Staff and Patients BERKELEY, Calif., Aug. 20,...
Peer-reviewed results published in Supportive Care in Cancer, the official journal of the Multinational Association of Supportive Care in Cancer...
TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to...
WALTHAM, Mass. and DUBLIN and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage...
WALTHAM, Mass., DUBLIN, Ireland and EMERYVILLE, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage...
Global patent estate encompasses 80 issued patents and 40 pending patent applications Strengthens strategic position in a multi-billion-dollar market opportunity...
These recent LungFit PH international agreements bring the ex-U.S. total to 34 countries and a combined population of 2.7 billion...
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical...
Pre-Treatment with blarcamesine entirely prevented Abeta-induced cognitive decline Confirmed significant biomarker-response in hippocampus NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE)...
Positive givastomig Phase 1b dose escalation data in combination with immunochemotherapy in patients with 1L gastric cancers presented at ESMO...